IceCure Announces Shero Imaging is First to Offer Breast Cancer Cryoablation Procedures in Missouri with ProSense®
MWN-AI** Summary
IceCure Medical Ltd. (NASDAQ: ICCM) has announced that Shero Imaging in St. Louis, Missouri, is the first clinic in the state to offer breast cancer cryoablation procedures using its ProSense® system. Recently receiving FDA marketing authorization, the ProSense® system allows for minimally invasive treatment of low-risk breast cancer by freezing tumors, presenting a less invasive alternative to surgical removal.
Shero Imaging, under the leadership of board-certified breast radiologist Dr. Tish Singer, aims to enhance patient care by providing cutting-edge treatment options. Dr. Singer emphasized the clinic's commitment to making advanced technologies like cryoablation accessible to patients nationwide, thereby expanding treatment options in a patient-centered environment.
IceCure’s Vice President of Sales for North America, Shad Good, praised Shero Imaging's initiative, highlighting the clinic's efforts to extend beyond diagnostics into treatment using ProSense®. The cryoablation procedure is tailored for women aged 70 and above, particularly those unsuitable for traditional surgical treatments, and is aligned with proposed guidelines by medical societies for approved patient populations.
The ProSense® system distinguishes itself as a versatile tool utilizing liquid nitrogen to create large lethal zones, effectively targeting both benign and cancerous lesions across various organs, including the breast, kidney, lung, and liver. This method not only accelerates recovery and minimizes pain but also significantly reduces surgical risks and complications.
IceCure Medical continues to develop innovative cryoablation therapies for tumor destruction, with the ProSense® system being its flagship product. The company remains optimistic about the integration of its technologies into clinical practice, expanding the landscape of breast cancer treatment options while addressing the evolving needs of patients.
MWN-AI** Analysis
IceCure Medical Ltd. (NASDAQ: ICCM) has recently made a significant advance in breast cancer treatment by launching its ProSense® cryoablation system at Shero Imaging in Missouri, marking a pivotal moment in the accessibility of innovative cancer care. Given that the FDA has authorized this system for specific low-risk breast cancer treatments, the company positions itself as a leader in a burgeoning market, particularly for older women who may not be viable candidates for traditional surgical options.
Investors should note that this expansion into Missouri could serve to enhance IceCure’s market presence and improve revenue potential, especially as more clinics across the U.S. consider adopting the ProSense® system. The inclusion of cryoablation in proposed medical society guidelines indicates a validation of its efficacy, which could lead to an uptick in clinician endorsements and patient adoption.
From a financial perspective, visibility is crucial. IceCure should focus on its marketing strategies to educate medical professionals and inform potential patients about the benefits of cryoablation. This includes emphasizing the technology's minimally invasive nature, rapid recovery time, and reduced complications compared to surgical options.
As IceCure continues to expand its operations, investors should closely monitor developments around regulatory approvals and reimbursement pathways, as these will significantly impact the company’s growth trajectory. The forward-looking statements regarding future guidelines and market adoption provide optimism but warrant caution, as market dynamics and competitive developments can shift rapidly.
In conclusion, IceCure’s entry into the Missouri market via Shero Imaging presents an exciting opportunity for growth and innovation. Investors should consider both the potential rewards and the inherent risks in the evolving landscape of cancer treatment technologies. Careful monitoring of IceCure’s strategic execution will be key for making informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
ProSense® system recently received FDA marketing authorization for the treatment of low-risk breast cancer
Cryoablation for breast cancer is now included in proposed medical society guidelines for the approved patient population
CAESAREA, Israel, Feb. 11, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the most recent purchase and installation of the ProSense® system in the U.S. at St. Louis, Missouri based Shero Imaging, the first clinic in the state of Missouri to offer breast cancer cryoablation with ProSense®. Shero Imaging is dedicated to delivering exceptional care by providing their patients with the choice of a minimally invasive treatment. ProSense® procedures will be conducted by Shero Imaging's founder and board-certified breast radiologist, Dr. Tish Singer.
Dr. Singer commented, "Shero Imaging is bringing IceCure breast cryoablation out of the ivory towers and making it accessible to patients across the country. From our St. Louis facility, we are thrilled to announce the addition of breast cryoablation services—an advanced, minimally invasive treatment option for women seeking cutting-edge care. This system perfectly complements our philosophy of delivering the highest level of care with state-of-the-art techniques in a comfortable, patient-centered environment. We're proud to bring this innovative technology to our community and provide our patients with expanded access to cutting-edge breast cancer treatment options."
"It is highly encouraging to see innovative breast care centers like Shero Imaging be in a position to grow beyond diagnostics and imaging into treatment with ProSense®. Breast radiologists are uniquely well qualified to adopt ProSense® to immediately freeze cancer in its tracks for the indicated patient population," stated IceCure's VP of Sales, North America, Shad Good. "We applaud Shero for being the first to bring our minimally invasive treatment option for low-risk breast cancer and fibroadenomas to women in Missouri."
About ProSense®
The ProSense® Cryoablation System is the first and only medical device to receive FDA marketing authorization for the local treatment of low-risk breast cancer with adjuvant endocrine therapy for women aged 70 and above, including patients who are not suitable for surgical alternatives for breast cancer treatment. A full list of benefits and risks can be found on the Company's website.
ProSense® is a minimally invasive cryosurgical tool that provides the option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including in the breast, kidney, lung, and liver.
ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable design and liquid nitrogen utilization, ProSense® opens the door to fast and convenient office-based procedures for breast tumors.
About IceCure Medical
IceCure Medical (NASDAQ: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and Asia.
Forward Looking Statement
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses the proposed inclusion of ProSense® cryoablation in medical society treatment guidelines. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC on March 27, 2025, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Logo: https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg
SOURCE IceCure Medical
FAQ**
What impact is the introduction of the ProSense® system by IceCure Medical Ltd. (ICCM) expected to have on breast cancer treatment accessibility and patient outcomes in Missouri?
How does IceCure Medical Ltd. (ICCM) plan to educate medical professionals about the benefits and effectiveness of the ProSense® cryoablation system following its launch in Shero Imaging?
In what ways does the ProSense® system by IceCure Medical Ltd. (ICCM) enhance patient value compared to traditional surgical treatments for low-risk breast cancer?
What are the potential risks and challenges IceCure Medical Ltd. (ICCM) may face in expanding the adoption of cryoablation therapy in other U.S. states beyond Missouri?
**MWN-AI FAQ is based on asking OpenAI questions about IceCure Medical Ltd. (NASDAQ: ICCM).
NASDAQ: ICCM
ICCM Trading
0.03% G/L:
$0.6141 Last:
21,662 Volume:
$0.62 Open:
